Emerging from stealth, RecovryAI introduces AI-powered, physician-prescribed Virtual Care Assistants for post-operative recovery
SAN FRANCISCO–(BUSINESS WIRE)–RecovryAI today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Virtual Care Assistants (VCAs), physician-prescribed, patient-facing clinical AI designed to support patients during post-operative recovery. The designation, reserved for medical devices that address serious conditions and demonstrate the potential to meaningfully improve existing standards of care, enables earlier and more frequent engagement with the FDA while maintaining the full requirements for demonstrating safety and reliability. The milestone coincides with RecovryAI’s emergence from stealth following more than two years of product development and clinical evaluation.
Post-surgical care in the United States has fundamentally shifted outside the hospital. More than 80 percent of procedures are now performed on a same-day basis, leaving patients to recover at home during their longest and least-supervised phase of care, including the first 72 hours, where the majority of complications occur. Early signs of complications can go unnoticed, discharge instructions cannot cover every question or situation, and providers lack continuous visibility into patient recovery between discharge and follow-up visits, increasing the risk of avoidable emergency department visits, readmissions, and delayed intervention. At the same time, care teams are burdened with high volumes of routine patient questions and recovery updates, limiting their capacity to focus on higher-acuity cases.
RecovryAI’s Virtual Care Assistants are designed to extend continuity of care from hospital discharge into recovery at home. VCAs are physician-prescribed AI that deliver recovery guidance based on established clinical protocols and escalate deviations from expected recovery patterns to the prescribing care team with full clinical context. RecovryAI’s initial VCA focuses on total joint arthroplasty, with the architecture designed to expand across procedural domains, subject to regulatory authorization.
RecovryAI is pursuing FDA authorization under a novel Class II pathway for patient-facing Software as a Medical Device (SaMD). The company has engaged the FDA through the pre-submission process since 2024 to align on clinical evidence requirements, with full submission expected later this year. If authorized, this decision would establish a new device classification and the special controls governing future devices in this category.
“Healthcare innovation will not scale without trust,” said Scott Walchek, CEO and co-founder of RecovryAI. “Most healthcare AI today lives in two lanes: clinician-facing tools like decision support and ambient documentation, and consumer health and wellness applications. Patient-facing AI inside the care pathway is different. It guides behavior and carries clinical responsibility. In this lane, trust is underwritten by FDA authorization. Without it, there’s no durable basis for safety, accountability, reimbursement, or real scale. From day one, we built within a regulatory framework and embraced the rigor clinical deployment requires.”
RecovryAI is currently conducting its pivotal clinical study evaluating the safety and system behavior of its Virtual Care Assistants in total joint arthroplasty recovery. The multi-site study includes OrthoArizona, one of the nation’s largest orthopedic practices, and Mercy Medical Center in Baltimore, MD, among other participating sites. Data from the company’s limited pilot phase showed that VCA system behavior generally aligned with physician judgment, supporting advancement into the pivotal study.
“Deploying generative AI in a regulated clinical environment requires a structured medical reasoning framework,” said Dr. Richard Watson, co-founder and Chief Science Officer of RecovryAI. “We designed our platform to continuously evaluate patient-reported information against expected recovery trajectories, deliver procedure-specific guidance when recovery is progressing appropriately, and escalate deviations to the prescribing physician’s care team with the complete patient interaction history and relevant clinical context. That architecture allows the AI to manage routine, low-acuity concerns while ensuring that clinicians retain oversight and exercise final medical judgment.”
RecovryAI is led by a team with deep clinical, regulatory, and technology expertise. Chief Science Officer Dr. Richard Watson holds more than 100 medical device patents and has led three prior FDA submissions. He and Chief Medical Officer co-founder Dr. Martin Sellberg, a 30-year emergency medicine veteran, previously founded and successfully exited a medical device company. CEO Scott Walchek brings four decades of experience building and exiting venture-backed technology companies across multiple industries, and Chief Product Officer Jesse Thomas adds more than a decade of healthcare technology product leadership.
About RecovryAI
RecovryAI develops physician-prescribed Virtual Care Assistants that support patients during post-procedure recovery. Starting with total joint arthroplasty and expanding across procedural domains subject to regulatory authorization, RecovryAI is building toward a future in which every patient is prescribed a Virtual Care Assistant upon discharge — infinitely scalable patient-facing clinical AI for a healthcare system whose demand is outpacing its workforce. The company is headquartered in the San Francisco Bay Area. www.recovry.ai
Contacts
Media Contact
Patrick Schmidt
[email protected]
